Reviewed by Peptide Treatments Medical Advisory Board (Medical Advisory Board)
PT-141: Evidence Summary
Evidence summary for PT-141 across studied indications. Each indication is graded using our evidence tier system based on the quality and quantity of available clinical data.
Back to PT-141 overview| Indication | Evidence Tier | Trial Count | Summary |
|---|---|---|---|
| Female sexual dysfunction (HSDD) | Tier A | 6 | FDA-approved as Vyleesi for premenopausal HSDD |
| Male erectile dysfunction | Tier B | 4 | Phase II/III data, not FDA-approved for this indication |